ALUR - Earnings call transcript Q3 2024 | Allurion Technologies Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Thank you for standing by. My name is John, and I will be our conference operator today. At this time, I would like to welcome everyone to the Allurion Third Quarter Earnings Call. [Operator Instructions] I would now like to turn the call over to Mike Cavanaugh, Investor Relations. Please go ahead.

Mike Cavanaugh

you joining thank today. and morning, all us for Good as press Incorporated financial September Earlier the well Technologies highlights. a recent XX, review release business company's as ended today, Allurion quarter issued announcing of the results XXXX, a for

Commercial; of a Digital Vice call website Brian the announcement on are Conyer, Chris Executive Health; Officer; Shantanu Senior Gaur, and Vice You at copy the International Financial me of www.investors.allurion.com. With Adrian Chief can Wild, Officer. President, the access Chief President on today company's Geberth, Founder and

most volumes. Actual Before those XX-K the uncertainties. detail uncertainties and our that certain from in but we meaning call are Commission statements filed implied and in Exchange our XXXX. inform a our Allurion trials expectations the future, or GLP-X may cost described our on demand begin, and and regarding GLP-X XX, our new launch and of profitability use I'd timing like risks runway, materially expressed products drugs, burn of clinical markets growth recent or These result impact procedure for limited including with the not with comments contain to of the filings, in ability as differ in in elective March you the regarding outlook within including ongoing our and our risks expectations initiatives today's and mentioned combination Securities and to ability results and program market financial on products laws, to on federal reduction cash securities drugs XXXX, of the forward-looking and the for and compete procedures, to regarding expectations

being statements any this our or SEC's statements. Allurion release through Please that undertakes can obligation forward-looking conference at website note publicly is are for page Events will not undue after to and revisions no at such reliance call to on and filings published Today's conclusion forward-looking our recorded with data been under to the be available Shantanu. Investor release cautioned our or turn have tables company SEC Relations replay audio on call. website call allurion.com place the our I'll to update And Our on that, and the shortly over website. press this on website. Investors financial found supplementary the investors.allurion.com these be section Presentation & to of

Shantanu Gaur

and, you morning, for us thank as always, joining today. Good

we've about composed our team, shareholder maximize had value year tangible announcing to in excitement have and our forward on capitalized weight challenging Allurion massive today, the for While we products, truly to given I of not a the have which financially, are and clarity date. X path levers we loss, opportunity

I've a also for which We of discuss impact but touched believe on past, significant the will the our XXXX. in can only success have in shareholders product, AI

us also a in will and our efficient slated about preparation for AUDACITY for for trial hear given business, You and that commercial end U.S. of the very we readout globally more we potential. strategy both ever-increasing its talk our market demonstrates full have the Balloon have that works year. deep effectiveness as plan well have realize data conviction its Balloon I this to a now our platform

financials. discuss let's First,

during which $X.X a prior revenue product was reduction revenue for quarters. in million quarter includes in Third million, quarter to France recalled that $X.X was of third sold the

U.K. macro and the drugs quarter compounded of certain of suspension and in in the Our Allurion in performance some cases this by headwinds France, the markets, was the Balloon counterfeit adversely affected in GLP-X launch

remain providers ANSM markets temporary the in of We particularly optimistic patients we where future, quarter, a soon remediation off We October. the in France. In of volumes disruption similar that after GLP-X to in X America be plan in from a a third with Middle a possible. We macroeconomic the commercialization in as action taken procedure strength tailwind certain for Middle about completed In we to in in growth therapy appear taken parts by have incur year and second while became believe that by patients see outside authority regulatory but of the part France short-term be recovering the drugs like Latin markets as Allurion. more phenomenon any and grew program. line no to who believe for quarter, that introduction other has we areas occurring by belief as out credence the East, did in headwind, that a their worked resuming approximately been our GLP-Xs, compared other of the Allurion last of We we third which doctors to driven similar play other lending aware and East now addition, in had France, what we actions on may may in is some tried is a standpoint. year believe in churned XX% GLP-Xs returned the long-term

One And Suite, Care a over from to things provide is seen I native of that the to further most Allurion will the by line VCS, platform, quarter a significant led Virtual This Brian or in for our him time have exciting pass row. AI third the is business first details. Conyer. in it have growth for to today announce we I recurring revenue

Brian Conyer

business that to We've for about quiet our me product add I've Allurion shareholders. record it's almost been digital at digital Allurion's and track been Shantanu. dataset a footprint a lines. of AI global right products we a entrepreneur. as our value health for rich until very as driver Thanks, year and now traction, with always a looked for could digital be I've now have but clear

than business expand different coming seeing in remote by monitoring agent the revenues where Our in plan was XX/X I line our we prescribing AI in expansion far. We're AI weight this With testing coaching. I'll the exploring the turn at growing for XX% months, cases grown driven Europe we from year-over-year, patients Shantanu. look resources forward for our double have a first more growth having loss and including States. AI first on invested revenues United GLP-X cases end. as now and believe and product use Iris, we're and patients in by further revenues in increasing option. into back growth our exciting thus This products to the despite conversational verticalized Coach to year track the GLP-Xs this over and to taking XXXX for future, patient can minimal pace, on a are in seeking use these reonboarded GLP-Xs in We who need near team call

Shantanu Gaur

Thanks, Brian.

for the calls clear strategy third for in a for decisive quarter value and to XXXX performance maximize Our shareholders.

penetration a the scaling France. plan one, consumer AI of platform by pillars. and markets profitability Allurion in in of commercialization product Number to four, launch. two, for Our around is direct marketing. focused built business Number for DXC And a consumer, Balloon or proven to models. the business FDA Number plan preparing smaller through to five, or and resuming Number new commercial BXBXC direct achieving versus end approval footprint, the number new ed our business U.S. variety business XXXX. on X marketing deeper now for a three, gaining U.S.

new control of of a other plan. and reality, can pressures is the we what remain control our outside While headwinds our macro execution

channels. it's that online on Before on aspects the plan, I of our see strategy advertising on have primarily more I reflect commercial helpful how XXXX, employed DTC think reliant the new through we strategy to historically it we to certain be I changing. In shifted expand and marketing heavily

the year, DTC least stimulated by by channels X%, this spending drop in While growth was replaced less but with strategy telehealth procedure strong efficient. spend more initially compared that GLP-Xs, became XX% and third part in crowded of the DTC DTC. marketing the we This organic back year DTC indicating offering demand increased top rise these volumes In dialed lost by line companies quarter, prior being in at to to our reduced the growth. the still our

return that in with third reliant in deploy well-versed XXXX, a quarter sustainable growth a underscores we strategy need DTC in in on BXBXC the more strategies. profitable order less team to to performance and even Our to

Senior to the now commercial new the by further details on Vice will of led Commercial. Our over provide Adrian hand Wild, to I'll President strategy him call strategy. be International

Adrian Wild

excited Allurion's commercial moment. leading pivotal at Thanks, be Shantanu. this efforts to I'm

strategy Invisalign, where shifts by especially medical is the achieved oversaw I commercial significant inspired profitable other our cash in new X successful devices, markets in major Our pay approaches for growth a strategy approach. overseas manner. taken decade involves expansion by and This new in a over

First, we are and our are who from experienced BXBXC with in bottom individuals top strategies. sales sustainable team deploying profitable to retooling

each a commercial role. plan profiles have skill and We in and right talent the mapped in we sets the team ensure have to implemented our we already need

Second, that bariatrics will where on with profitable of consultative a growing that Deploy including and we is exit high deep sales we in markets a entail will in number than core have focus decade. channels the rather on strong focus and including productivity increase approach our markets relationships This going potential. we less on changes, account built focused doubled down wide. past

business. will and deploying rigorous the We we this commercial our forecast outcomes efforts ensure decisions, enable the yielding believe desired organization us make related Third, more account planning, to and that the to are informed management more commercial reliable forecasting. execution for sales processes are throughout

look this forward several quarter and turn of expanding call this to in have near strategy approaches I are We seeing the the that, to already future. begun traction. pilot over globally positive back I will to With Shantanu. these

Shantanu Gaur

Adrian. Thanks,

to focused implement to sales is more resized we these and goal changes, create us can As growth. team that our return a

as some of making, are it realize and benefits fully several to are to breadth changes Given disruption with expect will depth take changes from many short-term that come the quarters it the implemented. we the the we

flat XXXX. $XX revenue we the procedure volume $XX to As result, range of to expect million to to XXXX compared million in be be and a

believe In we have initiatives, commercial decrease also a strategically lower headcount half and addition restructuring, allow by structure, functions streamlined on profitability centralized will high team, us base in to have narrow the operational burn. focus approximately our we the of in we cost our under and are significantly which leadership. bolster global a list to making cash result consolidated this Through and impact we changes reduced

these operating XX% in expect of in in result Taken a to reduction together, changes expenses we XXXX. approximately

streamlined more commercial and combination of move the operating We have for business right strong structure that the conviction our in long is term. change the strategy over the

for to last patient for Turning readout I'm very of end trial, on AUDACITY another us application proud of to are modules we submitted application, a the team to our In to allows in the at FDA. critical the when FDA that the discreet the milestone exited the to year. sections data PMA putting of premarket track for we the applicants process. modular or for very also first three FDA application pathway, our review our achieving October PMA approval the the pleased improve has of share the efficiency submit

and clinical the massive in expect module that been Balloon that We PMA final the on if drugs. United availability the can for fourth the believe data AUDACITY next of containing created FDA, the capitalize year. We of GLP-X the trial to by States by early has Allurion approved opportunity the submit the

benefits the as discontinuation. In addition PBM, off In GLP-Xs who healthcare line have after and regaining States that of the there's Prime with XX% actually for only on by their GLP-Xs, study who even a attractive in the We Balloon remained a for a either United later, Balloon Therapeutics, the the Ozempic a Allurion started people years of Wegovy of costs combining increased are Allurion an GLP-X to can highly taking or be we over and believe patients Allurion we period. bigger data trying for recent opportunity Balloon believe second the published this alternative therapeutic X millions the treatment patients then churning X-year weight. on GLP-Xs, it

adolescents VCS, Chris, Before a continue showing on I patients want the patients data to study virtual published with and areas passes. touch the reduction achieved through I without weight ongoing we study the X announced support In actually turn In XXX our including, that publication August, in serious advantages adverse we a Allurion the after XX Balloon. which impressive been underscore can first, that Balloon expand of of September, the and in indication, weight studies program potentially the that to in of call recently lose the any Allurion has the on Allurion over could XX% a to or presented events. guidance therapies the even over announced we who publication other

of months X the XX.X% validate our I geographies. peer-reviewed am and Very their a of change of third, a Second, Chris? a Chris call patients now XX% Chief the with lost improvements market. Society's total Allurion meta-analysis on real-world the bullish just I XX.X% of obesity patients Allurion largest-ever In Geberth, muscle studies mass. Recently, than countries. a dynamic average patients conference, weight weight X,XXX role remarkable And X weight program. Financial that can We at across at our now XX XX collectively treated XX.X% growing and experience average efficacy reporting will experience, program program maintenance simply, across X study of reduction presented publications safety XXX in reduction in journal an just turn showing consistency body Allurion months, Obesity comorbidities. and in in ever more and rapidly this real-world in significant of the weight over the we annual year the the significant play to XX in program no works, and with patients Officer. have the an after XX,XXX

Christopher Geberth

Thank you, Shantanu.

the impacted to to of accounts labor Our for volumes, million the reflected XXXX, manufacturing, product and rates overhead to period which for reduction million period quarter lower the third certain was period, XXXX of in to same the manage the resulted product macroeconomic to in France revenue revenue the suspension production in same third recalled and XX% quarter reorder markets, headwinds in the related and temporary to into reduction for third was sales compared in France certain recalls reductions credit sales destocking, to being quarter profit absorbed less in for in in the the decrease for period negatively XX% of in the in The revenue compared XXXX lower the risk. Gross by to the revenue year-over-year in inventory costs. $X.X leading resulting XXXX. $XX.X during and period

million less quarter profit the reduction with gross for largely fourth recall by fourth and our in reduced by million marketing Health product driven quarter, XXXX profit efficiency, business implemented expand expenses operating operations the cost transaction-related now France decrease the Compute offset in reduce or The to related to $X.X by million XXXX quarter complete. Sales for decreased combination expect quarter marketing third gross recognized We from $X.X period of in and and $XX.X XXXX by combination the million the to in the million expenses operating increased with and of million sales. related stock-based in driven loss from quarter quarter XX% compensation costs, expense DTC of our General $XX.X million and $X to stock-based recognized lower Compute million reduced by of million, compared third Research development million $XX.X efforts expenses the was XXXX. to $XX.X driven Health quarter administrative by bad less of decreased expenses the expenses costs with in in to third debt driven the in business the of operations quarter $XX the $XX from recognized by partially trial. expense transaction-related expense FDA of XXXX. decreased decreased in quarter, of third the related in third and of same $X and our and by compensation $X.X the compared to AUDACITY million to by to XXXX. Loss initiatives

Shantanu. to September $XX.X back of equivalents will of turn had and I now XX, over the call cash As million. XXXX, we cash

Shantanu Gaur

Thanks, Chris.

commercial changes strategy making around are Balloon. and We people, and our to business significant profitable the our sustainable processes in and difficult a Allurion our create

growing top safety clinical obesity to ahead and And support efficacy remains firmly us grow. meaningful, line by Balloon, library We the as the data of continues these market growth. Allurion demonstrated the the in steps of Allurion of to opportunity right intact. the also of that are firmly return The are convinced sustainable to

entrepreneurial We VCS Allurion also return believe of could business, are that GLP-Xs inside SaaS our rise the driven growth by growth. accelerate and we in top to experiencing nimble and line of a the team our

customers, will become look and managing has to weight we different platform of months the I in on to be the number testing our use forward to therapies, come. a loss vital AI-native Our different patients cases

Geberth dedication partner for Allurion. for to Chris I to like better asked X his with. service past I'd a not could navigate have thank and the Finally, years to

remain During Tara our the conduct ], who search will as to Brady the period, will call open we the on assist of consultant as for replacement. With turn call. now up as please serving will and questions. [ transition portion Operator, Chris a CFO the his our permanent will questions-and-answer for over a be I that, interim call

Operator

with Instructions] [Operator question line Our Cowen. comes of first Jennings the Josh from TD

Joshua Jennings

for well. those chapter of talk, about be start filing, to sure can I share your remind submitted X just on, X Thanks up? is X once the appreciated. wanted modules on hear Shantanu, FDA? Chris, just have interactions will would but submitted. hand as to for I departure, Any PMA be you data off waiting just mean, been thorough next with I'm modules packaged exciting. details module us, your signed be just in clinical the the can download the And And sorry and out you that data to

Shantanu Gaur

Absolutely. the Thanks for question, Josh.

an X first a variety the and quality of assessment including also testing system manufacturing of an related verification, processes certain PMA and regulatory The the topics, of benchtop and modules SOPs. controls of validation assessment our our to product, cover

by X have all been those of so And the They filed. FDA. are modules now being reviewed

addressed FDA to So around questions posed modules, we've some been minor far, X been the those have very the with conversations positive us. have that and

do well X, communicate we we up X, submission. and to AUDACITY may that part X this the as the externally have acceptance modules very well. is and module that of data then next as plan of Our X readout package year with end complete Once year of at early the

Joshua Jennings

Virtual was first better is I in Suite. of unleashing in today? to your you where patients onboarded process know the model like sounds revenue generation hoping the stands team U.S. out the I Care the understand it And GLP-X called just it

And Balloon more just approval patients. and I question details path U.S. so a Allurion guess their in with high-level the prior And the collaboration onboarding in about it's then the this well terms on of revenue just generation. Medtronic as to

looking Care would a question more little Virtual great. be Sorry, just but general a bit detail Suite, it's on for

Shantanu Gaur

Yes.

are and a or and different product AI is providers the Suite Our or of GLP-Xs. patients it's whether interventions, VCS Balloon monitor really who loss product. Allurion Virtual the It coach outside a to through versatile the variety allows weight United Care follow quite going States,

Now in both use we're our ramp seeing U.S. Josh, the up patients you care even platform, on with Medtronic, was virtual GLP-X that, partnership therapy the of part the our surgery. bariatric channel. surgery bariatric if U.S. suite also the subject the outside with our expanding recall, of in And and or of

in provider a served balloon so in obviously, GLP-X the practices using in to those interesting providers will we patient the the high-volume The basis. on They're us and the patients. busy seeing loss we're today, the for that are the What an Once a monitoring X generation on And can because is patients actually to volume X call are in fee surgery, Virtual of infrastructure using all month where way GLP-Xs, now, balloon very who features also Allurion But focusing product and behavior not are of that's really don't increase nowhere patient paying patients revenue device, change. use near FDA we on version really features. patient have in happens more have not given we today. the what GLP-X directly the also GLP-Xs clinical approved, adherence work of the per per drug, that rise basic version gets any don't and we're our doing but of are U.S. program. the coaching. we of are on that U.S. as month the per sort gives be offer AI providers the patient weight more trial a VCS follow we those these model the but Virtual Care and orphans. you a Suite any per software access a Care One, because, Balloon And and to suffer. type month any the And results That sort providers monetize all is a those given with U.S. Suite. really would premium as rates twofold. VCS as change on well, of they're of as result, per They're a efficacious a per given see model. a

of software now a So potential U.S. are our we in millions. with because the see there lot

tried GLP-X and in weight to fact, they adults have and that need coaching, future. and majority order the In follow-up in treatment the not it of them X the in now are actually U.S. a getting X the keep vast the off lose

Joshua Jennings

XXXX just more. question. Know multilayered not Maybe Excellent. one but you're guidance, a giving

France Just think can the just our virtual to high maybe even XXXX. at we're France, also, models? recovery in then be and XXXX but about you point, this thinking contributions XXXX the should how probably in we anything from impossible suite on trajectory updating detailed $X.X-plus revenue care a contributions about AI revenue or color share on a help platform? thinking And in level as the the about was business the recovery Maybe forecast just that million us franchise in

Shantanu Gaur

we're Yes. any With had France, to to productive to offering with ANSM. conversations we not guidance XXXX, have very With regards date. regards

any sort about get And we're breaking at of With remain to sort massive. point. product As to regards to from general resuming up heard will awaiting optimistic ANSM AI out back massive. when We're really GLP-Xs, not onboarding for now but XXXX it I contribution this France VCS we with point August earlier, the at at any of in the commercialization. the in When from VCS, you U.S. volume and did back product many this U.S. the AI about it's submit in remediation all getting are practices plan very would the think look completed market revenue feedback line of on France to benefits how brings these the separate now ANSM, when We're difficult in in hence, the really at the our you a the market say and September. provide France. not providing on in to that that and busy on potential VCS weight you failing in keep and to that from see is you busy product yet. outside are I our practice, just how people product our look Balloon loss potential like But ours and an is time revenue

So we're not growth. breaking could accelerate our and it out business very return believe top high for it's now, our but a to I part of potential line

Operator

Our the next of with from line comes Taylor question Matt Jefferies.

Matthew Taylor

jumping on XXXX, model. in bit margins be gross very to the and about be whether for one first how think is off point in you revenue you XXXX? helpful you And to think more any a to produce So that ask QX little specificity for a was, I the help if able could that with wanted them do in us in U.S. may would

Shantanu Gaur

Yes.

to on to virtual timing terms of In for of we're this it's U.S. what Allurion Balloon. our revenue to At expecting care the XXXX, difficult the side look business. point, some come going FDA the is product assess like AI suite

offer that's to So all And Chris. it we of over in on your to now, terms question XXXX. really I'll margin, with can hand for regards

Christopher Geberth

Chris. it's Matt, Hey,

in all with margin still to we're the also lower have operations, mid-XX France that And without implemented looking I could expect November, to just goes, the our would forecast. were that margin as down. as So we restructuring XXXX. to up our we the volume recall impacted in QX, the by been and at negatively our revenue related the adjustments, and for low charge mid-XXs across And reduction as accrete year, departments, we those that numbers through back Margin that in expect would in towards would mostly area. recall. to I then was far of be the including the And XXs that without that volume, end see low in goes took the would France it margin

Matthew Taylor

the in of Okay. a to that ask specificity with I expenses, of talking is coming you have historically quarter. $XX.X reduction as I Great. that's you with X% to overall relied to And you comment about know whether from next a year, guess R&D then us can midpoint the I the bit to out follow-up look DTC for But guess a sales drive I want restructuring. at and When reduction G&A? DTC more revised between that I'd demand. about you little you million. help of the one lot on you're can you And XX% you love did grew XX% on and marketing, where volumes grow this think guidance

Christopher Geberth

Yes.

all and to So efficiency revenue work XXXX. end evaluated forward, and that looked profitability me date the I achieved the towards structure departments, gain the start at we've we then with ways at the restructuring. we reason did forecast the across to why let and mean, considering levels going we of really the entire

all change of the are equal the side especially And see does reduced, in are sales what each from So kind of cautious expense we about reductions we across what in a you departments. XX% would but really that department. department, really

you the increased have out instance, with the a pointed marketing of order of customers. lower number but we just like sales more our our did DTC, lot to effectively we expenses, work For department heads with in in

say, restructuring also, the half efforts. half commercial the out without our would second going numbers we forward for plans, weighted laid I expect complete that mean, towards there's versus would last in of plan France growth. So you more ourselves in remarks that in know, commercial the work the Shantanu the And of the in year, But to the be I especially to ramp-up through strategy to period. that change XXXX, prepared I expect any back get year, first I as with our order positioned revenue a think regarding would growth we as

I really as said, several take get to Shantanu benefit it quarters think full could the those changes. of

I next first and QX business and sort we're in then for growth half is looking second a base think at half. the in So year, of the

Operator

line the from of Jason comes Capital. with question next ROTH Our Instructions] [Operator Wittes

Jason Wittes

this Just could you the quantitate beginning, in you France destocking quarter? said from you in can the impact if and the maybe,

Christopher Geberth

we just haven't give plus to of went say recall against for have France, in we of revenue. a that would adjustment used it's, would to our So revenue. about had I it acknowledged that we be France numbers, before million France, had over that XX% $X.X $X million some

an in So but take prior we to the not that the for related inventory that sales in accounting current for where had this requires periods was adjustment period. purposes back sales and against to related to quarter, revenue

Jason Wittes

it. in reduction terms the end next is the And that plan, or implemented Got will reduction? that year? staging that of then that Or over Great. -- did that of that What completes correctly the quarters? is few by hear of Okay. the -- be something on that, is I cost the kind

Christopher Geberth

Sure, Jason.

a in So implementation with we already started of actually the and this reduction force expenses.

in that fourth come So of will quarter. the most

will of be the above just the be in a need first But There some costs in of is people that have the QX, charge done. normal will but should short operating approximately term. in not that the it will We in contracts that fourth $X.X complete be most most quarter. done million But of some in quarter related, trend expenses. to

Jason Wittes

you're this cost think then And here. end breakeven way that right sort of follow-up XXXX, about new correctly it? the reaching committed of Did to still it. that sort of I Is again, especially structure? Got by hear Okay. kind another the question of with to

Christopher Geberth

Yes. at measuring EBITDA of a What late adjusted profitability. target is XXXX we're looking

Jason Wittes

be? were regional I and Were you don't drivers the in around can others maybe And Okay. there commentary stronger kind of know might terms what Great. give revenues if of regions discussion how certain that some then look. than any

Shantanu Gaur

did to is then lot this note X East, Balloon we're And it see weight have also looking of past approximately hype. both part of and, in witnessed start that their quarter, is well months, lot actually in doctor we've volumes. launched a starting churn excitement with seen surgery Yes. previous where their back and seen and the ago Middle XX a is launched that overall that quarters the One as a of off, we they regain for bariatric year we of to what GLP-Xs the What in world the a recovery GLP-X, therapy. a thing we've business, patients come over second-line frankly,

help XX% really providers the of More combination can XX% anti-obesity of previously That's more up that of in So America, GLP-Xs that with previously, seeing have business. our Balloon saw GLP-Xs. in Allurion in an using America. that's, are some the in tangibly favorable of as mature. talked of to which world GLP-X some medication. our led from to our is every Latin may are growth phenomenon other one Latin see abatement I'd now how someone macroeconomic Allurion we're tried believe, we're is those have almost starting being for And the second-line territories fantastic see the who seeing tried has we and broadly, a therapy as that now say, a territory parts GLP-X, we year. we what about last off more is in what regained increasingly positioned I headwinds In we weight. markets churned And patients

us from seeing really asked in macro that volumes investment trends we're help was procedural future significant DTC some in So a to related fuel which positive marketing. could the actually earlier, without question a a perspective,

Jason Wittes

helpful. just very That's maybe last one And one. Okay. then

are going patients is patient? those what GLP-Xs In product, terms that kind your plus profile of that on of

Shantanu Gaur

body not are doctor lose and therapy. one that that demographic, GLP-X mostly GLP-Xs our between patient either weight our we a potentially their loss have to balloon Balloon tack in as maintain the I'm if the GLP-X, certain about for very near think launch then FDA weight so is losing these the XX. least not therapy a weight a the start very over the trying longer that's reverse Typically where female a practices the weight when U.S. is what they likely with may or that well safely BMI with found be opportunity of And online. in the mass Balloon weight either they're about or our is the and about loss is target Balloon, experience start first-line of their that in Many in launch the ready with lose VCS I as We're looking a GLP-Xs the they U.S. approved if and And VCS who Allurion can effectively. end are quickly, of a the or just excited very They their churn present, on and very patient mid-XXs plateau it's Balloon the They we have that platform on as they also may our GLP-X where bring is heard patients the them of perfect much it's likes combination when expected, online. States, our and a at of seeing right instance, off they onboarded index to Allurion United to a have well taking and things may in in with period residency had of through when to a their balloon combination are time. GLP-X, in that the are XX they provider continue and for

that interesting U.S. in States. the So here expand United software be we we'll footprint that's thing watching our of another the the in as

Operator

As there this any back are over time, turn the Shantanu questions further conference no remarks. Gaur like would to for closing I to at

Shantanu Gaur

much. Thank very you

I'd thanks clients today. just our we our time I shareholders, and who like and our really my support around everyone to employees. certainly close customers our here, of to your of As in us and world loyalty interest all We call continued joined the appreciate Allurion. the and appreciate extend

company of forward inspiring all updating to progress And Have Your to again, our really you success. be and we a Thank on to everyone. is future our the next mission belief in in you great our our is look going and quarter. day. commitment instrumental to

Operator

your meeting. That you Thank concludes today's for participation.

now may You disconnect.

Allurion (ALUR) 13 Nov 242024 Q3 Earnings call transcript